![]() ![]() Clario's Trial Anywhere™ solutions have been powering hybrid and decentralized clinical trials (DCT) for over 15 years, enabling sponsors to collect high-quality endpoint data from any modality or location, all while improving the patient experience and diversity. Across decentralized and site-based trials, our deep scientific expertise, global scale and the broadest endpoint technology platform in the industry allows our partners to transform lives. For more than 20 years, Cogstate has proudly supported the leading-edge research needs of biopharmaceutical companies and academic institutions and the clinical care needs of physicians and patients around the world.įor more information, go to or follow us on LinkedIn and Twitter.Ībout Clario Clario is a leading technology company that generates the richest clinical evidence in the industry for our pharmaceutical, biotech and medical device partners. Cogstate technologies provide rapid, reliable and highly sensitive computerized cognitive tests and support electronic clinical outcome assessment (eCOA) solutions to replace costly and error-prone paper assessments with real-time data capture. ![]() To learn more about Clario's eCOA Multimedia, please navigate to the Clario website.Ībout Cogstate Cogstate Ltd (ASX: CGS) is a leading neuroscience technology company optimizing brain health assessments to advance the development of new medicines and to enable earlier clinical insights in healthcare. This partnership will continue to drive innovation for clinicians and patients. This expanded collaboration offers an approach that can meaningfully reduce rater and site burden while driving quality outcomes."Ĭlinical Trials can transform and save lives. Effectively balancing data quality benefits with operational ease can only be achieved when you combine deep domain expertise with capable and flexible clinical systems. "As a company, we have pioneered digital assessments of cognition as well as novel delivery models for rater training of conventional cognitive assessments. "We are thrilled to expand our partnership with the eCOA experts at Clario to support the full range of cognitive and clinical assessments critical to neuroscience research," said Brad O'Connor, Chief Executive Officer at Cogstate. That is what Cogstate and Clario have come together to deliver." "Fit-for-purpose eCOA functionality such as photo and audio capture and advanced workflow and scoring automations enable reliable and standardized data collection for cognitive endpoints when tightly coupled with industry-leading rater training and monitoring. "Clinical trials, particularly those in neurodegenerative disease, require sensitive, reliable endpoints that are delivered with a streamlined, patient-centric approach, integrating the range of clinical assessments across performance-based, clinician-reported and patient-reported outcomes," said Andrew Cooper, Executive Vice President, eCOA and Trial Enablement at Clario. This expands the companies' previously announced partnership to deliver Cogstate's digital cognitive assessments with Clario's eCOA platform offering a dramatically streamlined solution for digital and conventional outcomes with an integrated approach to hardware, training and operational support. It combines Clario's eCOA Multimedia technology for audio, photo and patient/clinician data capture with Cogstate's global clinical network and deep therapeutic expertise in neurodegenerative diseases. The collaboration drives enhanced data quality and signal detection for the full range of conventional cognitive endpoints common in neuroscience studies. Clario - The best of ERT and Bioclinica (PRNewsfoto/Clario) (PRNewswire)
0 Comments
Leave a Reply. |